

UNAUDITED CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS For the three-month periods ended September 30, 2019 and 2018



| Consolidated Statement of Financial Position | | | | | |
|--|--|---|--|--|--|
| As at September 30, 2019 As at June 3 (Unaudited - Expressed in Canadian dollars) | | | | | |
| | - | | | | |
| Assets | | | | | |
| Current assets | 07.040.040 | 07.040.440 | | | |
| Cash | 27,640,349 | 27,819,140 | | | |
| Accounts receivable | 13,042,096 | 15,016,481 | | | |
| Inventory | 7,296,582 | 7,589,896 | | | |
| Prepaid expenses | 871,912 | 856,672 | | | |
| Lease deposits | 10,200 48,861,139 | 10,200 51,292,389 | | | |
| Non-current assets | 40,001,139 | 51,292,369 | | | |
| | 04 244 | 01 244 | | | |
| Lease deposits | 91,344 | 91,344 | | | |
| Equipment deposits Right-of-use assets | 2,919,270 5,127,957 | 655,465 5,502,111 | | | |
| Property, plant and equipment [Note 4] | 32,322,760 | 30,575,332 | | | |
| Intangible assets | 4,128,399 | 4,267,929 | | | |
| Goodwill | 460,164 | 460,164 | | | |
| Total assets | 93,911,033 | 92,844,734 | | | |
| Current liabilities Operating loans [Note 5] Accounts payable and accrued liabilities Income taxes payable Deferred grant Contract liability Long-term debt due within one year [Note 5] | 2,535,180 13,229,359 266,646 43,970 443,834 5,661,290 | 1,339,480 14,712,219 285,433 231,745 2,512,994 4,170,072 | | | |
| Non-current liabilities | 22,180,279 | 23,251,943 | | | |
| Defined benefit liabilities | 1,132,748 | 870,329 | | | |
| Long-term debt [Note 5] | 18,444,751 | 20,692,925 | | | |
| Convertible debentures - Loan [Note 5] | 7,831,755 | 7,703,414 | | | |
| Deferred taxes liabilities | 2,075,349 | 2,230,398 | | | |
| Total liabilities | 51,664,882 | 54,749,009 | | | |
| | ,, | 2 .,2,300 | | | |
| Shareholders' Equity | | | | | |
| Share capital [Note 6] | 60,537,116 | 53,445,389 | | | |
| Reserve [Note 6] | 3,170,996 | 3,604,511 | | | |
| Convertible debentures - Options | 2,240,000 | 2,240,000 | | | |
| Foreign currency translation reserve | (6,909) | 12,927 | | | |
| Deficit Total equity | (23,695,052) 42,246,151 | (21,207,102) 38,095,725 | | | |
| Total equity and liabilities | 93,911,033 | 92,844,734 | | | |

See accompanying notes to condensed interim consolidated financial statements

Note 1 – Nature of operations and liquidity risk

Approved on behalf of the Board of Directors

Soroush Nazarpour

Soroush Nazarpour

Benoit Gascon
Benoit Gascon

1



Consolidated Statement of Loss and Comprehensive loss

| | Three-month periods ended September 30 | |
|---|--|-------------|
| | 2019 | 2018 |
| (Unaudited - Expressed in Canadian dollars) | \$ | \$ |
| Revenues | 19,983,089 | 3,907,726 |
| Expenses | | |
| Cost of sales | 16,937,762 | 3,376,516 |
| Research and development costs | 680,277 | 468,421 |
| Selling, general and administrative | 3,151,738 | 1,171,316 |
| Share-based compensation | 216,171 | 51,962 |
| Depreciation (production) | 749,745 | 323,033 |
| Depreciation (other) | 210,029 | 102,529 |
| Amortization | 150,277 | 15,854 |
| Foreign exchange | 36,221 | (27,408) |
| | 22,132,220 | 5,482,223 |
| Operating loss | (2,149,131) | (1,574,497) |
| Interest on operating loans, long-term debt and convertible debentures | (378,015) | (52,203) |
| Interest accretion on lease liability | (84,193) | (48,504) |
| Interest revenue | 117,022 | 36,371 |
| Loss before income taxes | (2,494,317) | (1,638,833) |
| Current income taxes expense | (43,981) | _ |
| Deferred income taxes recovery | 207,863 | 39,652 |
| Bolotton moonto taxos rocevery | 163,882 | 39,652 |
| Loss for the period | (2,330,435) | (1,599,181) |
| Other comprehensive loss | | |
| Items that may be subsequently reclassified to profit and loss: | | |
| | | |
| Exchange differences on translation of foreign | (40.026) | 0.400 |
| subsidiaries | (19,836) | 2,186 |
| Items that will not be reclassified to profit and loss: | | |
| Retirement benefits – Net actuarial gains | (157,515) | 60,377 |
| Comprehensive loss for the period | (2,507,786) | (1,536,618) |
| | | |
| Loss per share | (0.02) | (0.02) |
| Basic and diluted Weighted average number of common shares outstanding (basic and diluted) | (0.02) 447 884 802 | (0.02) |
| Weighted average number of common shares outstanding (basic and diluted) | 117,881,802 | 88,529,183 |

In light of the net loss recognized for the years, all outstanding conversion options, stock options and warrants and Broker Warrants were excluded from the calculation of diluted loss per share due to their anti-dilutive effect.

See accompanying notes to condensed interim consolidated financial statements



Balance as at September 30, 2019

Consolidated Statement of Changes in Shareholders' Equity Convertible Foreign currency Common Number of debentures translation common shares Reserve **Options** reserve Deficit **Total equity** \$ (Unaudited - Expressed in Canadian dollars) shares \$ \$ \$ \$ \$ 88,526,285 23,502,555 2,871,633 13,490 (10.629.691)15,757,987 Balance as at June 30, 2018 (1,599,181)Loss for the period (1,599,181)Other comprehensive loss 2,186 60,377 62,563 2,186 Comprehensive loss for the period (1,538,804)(1,536,618) Issuance of shares related to Sigma acquisition [Note 3] 5,091,707 8,197,648 8,197,648 13,333 8,801 (2.798)6,003 Exercise of stock options Share-based compensation 51.962 51,962 15,676 Balance as at September 30, 2018 93,631,325 31,709,004 2,920,797 _ (12,168,495)22,476,982 Loss for the period (9,004,184)(9,004,184)(34,423)Other comprehensive loss (2.749)(37,172)Comprehensive loss for the period (2,749)(9,038,607) (9,041,356)2,240,000 16,144,800 20,367,000 22,607,000 Private placement (net of issuing costs of \$621,240) Exercise of warrants and Broker Warrants 1,229,073 1,854,034 1,369,385 (140,312)Share-based compensation 824,026 824,026 111,630,159 53,445,389 3,604,511 2,240,000 12,927 (21,207,102)38,095,725 Balance as at June 30, 2019 Loss for the period (2,330,435)(2,330,435)Other comprehensive loss (19,836)(157,515)(177, 351)Comprehensive loss for the period (19,836)(2,487,950)(2,507,786)6,442,041 Exercise of warrants and Broker Warrants [Note 6] 7.091.727 (649,686)9.365.651 216.171 216.171 Share-based compensation

60,537,116

2.240.000

3,170,996

(6,909)

(23,695,052)

120.995.810

See accompanying notes to condensed interim consolidated financial statements

42,246,151



Consolidated Statement of Cash Flow

| | Three-month periods end | |
|--|-------------------------|-------------|
| | 2019 | 2018 |
| (Unaudited - Expressed in Canadian dollars) | \$ | \$ |
| | | |
| Cash flow from operating activities | (0.000.405) | (4.500.404) |
| Loss for the period | (2,330,435) | (1,599,181) |
| Items not affecting cash: | 4 440 054 | 444 445 |
| Depreciation and amortization | 1,110,051 | 441,415 |
| Share-based compensation | 216,171 | 51,962 |
| Interest accretion on lease liability | 84,193 | 26,090 |
| Interest accretion on convertible debentures | 113,542 | 40.007 |
| Other financial expenses | 217,194 | 13,337 |
| Deferred income taxes expense | (207,863) | (39,652) |
| Difference between amounts paid for employee benefits and current year | 108,468 | 9,247 |
| cost | • | 9,241 |
| Net change in fair value of foreign exchange derivatives | 22,796 | |
| Unrealized foreign exchange | (24,647) | (60,565) |
| Changes in non-cash operating working capital items: | | |
| Accounts receivable | 1,968,606 | 410,205 |
| Inventory | 289,872 | (34,111) |
| Prepaid expenses | (15,827) | (159,879) |
| Accounts payable and accrued liabilities | (1,498,180) | 107,333 |
| Income taxes payable | (18,080) | (473) |
| Deferred grant | (187,775) | (152,268) |
| Contract liability | (2,068,980) | 23,519 |
| Cash used in operating activities | (2,220,894) | (963,021) |
| Cash flows from financing activities | | |
| Exercise of stock options, warrants and Broker Warrants | 6,442,041 | 6,003 |
| Variation of operating loan | 1,200,000 | (40,000) |
| Repayment of lease liability | (503,362) | (212,720) |
| Repayment of long-term debt | (600,630) | (35,836) |
| Cash from (used in) financing activities | 6,538,049 | (282,553) |
| | | |
| Cash flows from investing activities | | (50.044) |
| Lease deposits | - | (58,044) |
| Equipment deposits | (2,263,805) | (7.000.400) |
| Business acquisition, net of cash acquired [Note 3] | _ | (7,300,496) |
| Business acquisition, balance of purchase price payable [Note 3] | (0.004.044) | 9,011,000 |
| Additions of property, plant and equipment | (2,231,041) | (58,304) |
| Cash used in investing activities | (4,494,846) | 1,594,156 |
| Change in cash | (177,691) | 348,582 |
| Net effect of currency exchange rate on cash | (1,100) | (9,653) |
| Cash, beginning of period | 27,819,140 | 15,268,666 |
| Cash, end of period | 27,640,349 | 15,607,595 |
| Interest paid | 356,682 | 116,918 |

See accompanying notes to condensed interim consolidated financial statements



[EXPRESSED IN CANADIAN DOLLARS]

[Unaudited and not reviewed – Unless specified otherwise, amounts are expressed in Canadian dollars]

1. NATURE OF OPERATIONS AND LIQUIDITY RISK

NanoXplore Inc., and its subsidiaries (together "NanoXplore" or the "Company"), is a graphene company, a manufacturer and supplier of high-volume graphene powder for use in industrial markets. Also, the Company provides standard and custom graphene-enhanced plastic and composite products to various customers in transportation, packaging, electronics, and other industrial sectors. The address of the Company's corporate office is 25, Boul. Montpellier, St-Laurent (Montreal), QC, Canada.

NanoXplore Inc. is listed on the TSX Venture Exchange and has traded under "GRA" and is also listed on the OTCQX and has traded under "NNXPF".

On September 21, 2018, the Company acquired all of the issued and outstanding shares of Sigma Industries Inc. ("Sigma"). Sigma has two active wholly-owned subsidiaries; Faroex Ltd., based in Manitoba, and Rene Composite Materials Ltd., based in Quebec. Rene Composite Materials Ltd has one active wholly-owned subsidiary; RMC Advanced Technologies Inc, based in Tennessee (USA).

Management believes that the Company has sufficient funds to meets its obligations, operating expenses and some development expenditures for the ensuing 12 months as they fall due. The Company's ability to continue its development activities is dependent on the beginning of the commercial operation of the graphene products. The graphene commercial activity is in the development stage and as a result the Company has minimal source of operating revenue from those operations and is dependent on external financing to fund its continued development program. The Company's main sources of funding have been the issuance of equity securities for cash, debt, funds from the government of Quebec with respect to R&D tax credits, from Sustainable Development Technology Canada ("SDTC") and from the Industrial Research Assistance Program.

The condensed interim consolidated financial statements of NanoXplore for the three-month periods ended September 30, 2019 and 2018 were reviewed, approved and authorized for issue by the Company's Board of Directors on November 26, 2019.

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of presentation

The unaudited condensed interim consolidated financial statements of the Company and its subsidiaries for the three-month periods ended September 30, 2019 and 2018 have been prepared in accordance with International Financial Reporting Standards ["IFRS"], as issued by the International Accounting Standards Board ["IASB"] and as adopted by the Accounting Standards Board of Canada. These condensed interim consolidated financial statements were prepared in accordance with IAS 34, Interim Financial Reporting.

These unaudited condensed interim consolidated financial statements are presented in Canadian dollars, the Company's functional currency, except where otherwise indicated. Each entity of the Company determines its own functional currency and items included in the financial statements of each entity are measured using that functional currency.

The significant accounting judgments, estimates and assumptions used in these unaudited condensed interim consolidated financial statements are consistent with those disclosed in the most recent audited annual consolidated financial statements for the year ended June 30, 2019.

These condensed interim consolidated financial statements have been prepared on a going concern basis, at historical cost, except for financial assets and liabilities classified as financial assets/liabilities at fair value through profit or loss and measured at fair value. Management considers that the fair value of financial assets and liabilities recorded in the financial statements approximates the carrying amount.

Basis of consolidation

The unaudited condensed interim consolidated financial statements include the accounts of the Company and its subsidiaries. The subsidiaries are using consistent accounting policies and the same reporting period as the parent company. All intercompany transactions, balances and unrealized gains or losses have been eliminated.



[EXPRESSED IN CANADIAN DOLLARS]

Standards, interpretations and amendments to published standards adopted with an effect on the unaudited interim condensed consolidated financial statements

The same accounting policies and methods of computation are followed in these condensed interim consolidated financial statements as compared with the most recent annual consolidated financial statements. The condensed interim consolidated financial statements should be read in conjunction with the audited annual consolidated financial statements and notes for the year ended June 30, 2019, except for the amendments to certain accounting standards which are relevant to the Company and were adopted by the Company as of July 1, 2019 as described below:

Borrowing costs

Borrowing costs that are attributable to the acquisition, construction or production of a qualifying asset are capitalized to the cost of that asset until it is substantially completed, and it can be used as planned; these costs are subsequently amortized over the expected useful life of the asset. All other borrowing costs are expensed as incurred.

3. BUSINESS COMBINATIONS

On September 21, 2018, the Company acquired all of the issued and outstanding shares of Sigma for a total amount of \$8,793,581 paid by the issuance of 4,579,988 common shares of its share capital to all existing shareholders of Sigma and acquired all the outstanding debentures of Sigma for a total amount of \$9,993,500 of which \$9,011,000 was paid by cash and \$982,500 was paid by the issuance of 511,719 common shares of its share capital to the Sigma debenture holders. The exchange ratio to determine the amount paid was based on a fixed price; each Sigma common share has been exchanged for 0.39 common share of NanoXplore. The value of Sigma common shares has been set at \$0.75 and the value of NanoXplore common shares has been set at \$1.92. This acquisition was concluded in order to introduce the Company's graphene-enhanced solution products into the products of Sigma.

Based on the stock price (TSX-V) of NanoXplore shares at the acquisition date of \$1.61, the fair value of the total consideration paid amounted to \$17,208,648 and is detailed as follows:

| | Number of shares | Fair value of shares | Paid by cash \$ | Total consideration \$ |
|-------------------------------------|---------------------|----------------------|-----------------------|------------------------------|
| Total consideration paid for: | | | | |
| All outstanding shares of Sigma | 4,579,988 | 7,373,780 | _ | 7,373,780 |
| All outstanding debentures of Sigma | 511,719 | 823,868 | 9,011,000 | 9,834,868 |
| Total | 5,091,707 | 8,197,648 | 9,011,000 | 17,208,648 |

This transaction was financed using the Company's available cash.

Sigma is a manufacturing company specializing in the manufacture of composite products. It operates in the markets for heavy trucks, buses, public transit, machinery and wind energy. Sigma sells its products to original equipment manufacturers and distributors mainly in the United States and Canada.

This transaction qualifies as a business combination and was accounted for using the acquisition method of accounting under IFRS 3, Business Combination. The total purchase price was allocated to the assets acquired and liabilities assumed based on the fair value of the total consideration at the closing date of the transaction.



[EXPRESSED IN CANADIAN DOLLARS]

| | \$ |
|--|------------|
| Identifiable net assets acquired: | |
| Cash | 1,710,504 |
| Accounts receivable | 10,495,837 |
| Inventory | 5,994,701 |
| Prepaid expenses | 342,324 |
| Right-of-use assets [Note 9] | 731,083 |
| Deferred taxes assets | 859,000 |
| Property, plant and equipment [Note 9] | 17,650,161 |
| Equipment deposit | 1,674,944 |
| Intangible assets [Note 10] | 4,405,673 |
| | 43,864,227 |
| Operating loan | 3,663,003 |
| Accounts payable and accrued liabilities | 8,137,899 |
| Contract liability | 2,779,946 |
| Deferred taxes liabilities | 2,613,057 |
| Lease liability | 731,083 |
| Long-term debt | 9,190,755 |
| | 27,115,743 |
| Total identifiable net assets | 16,748,484 |
| Goodwill arising on acquisition | 460,164 |
| Total consideration | 17,208,648 |
| The cash outflow on acquisition is as follows: | |
| Consideration paid in cash | 9,011,000 |
| Minus: Cash acquired | 1,710,504 |
| Net cash flow for the acquisition | 7,300,496 |
| | |

The goodwill recognized on the transaction is mainly attributable to the expected synergies of the combination, to broadening the service offering of the Company and its geographic coverage. The goodwill arising from this acquisition is not deductible for income tax purposes.

Transaction costs of \$174,140 were expensed and are included in selling, general and administrative expenses.

Since September 21, 2018, the assets and liabilities of Sigma are included in the consolidated statement of financial position and the operating results are reflected in the Company's consolidated statement of loss.

[EXPRESSED IN CANADIAN DOLLARS]

4. PROPERTY, PLANT AND EQUIPMENT

| | | | | Laboratory, computer, office | |
|---|------------|-------------|--------------|------------------------------|-------------|
| | Land & | Production | Leasehold | equipment and | |
| | Building | equipment | improvements | rolling stock | Total |
| | <u> </u> | \$ | \$ | \$ | \$ |
| Balance as at July 1 st , 2018 | 1,430,062 | 4,663,345 | 29,369 | 365,244 | 6,488,020 |
| Additions | 3,184,785 | 6,404,014 | 3,300 | 239,633 | 9,831,732 |
| Acquired in a business combination | 8,542,500 | 8,949,482 | _ | 158,179 | 17,650,161 |
| Disposals | _ | (1,330,641) | (640) | \ ' ' | (1,338,524) |
| Depreciation | (105,555) | (1,901,780) | (7,876) | (154,661) | (2,169,872) |
| Effect of foreign exchange differences | | 106,945 | | 6,870 | 113,815 |
| Balance as at June 30, 2019 | 13,051,792 | 16,891,365 | 24,153 | 608,022 | 30,575,332 |
| Additions | _ | 2,427,364 | 7,850 | 53,488 | 2,488,702 |
| Depreciation | (30,174) | (688,911) | (2,446) | (33,432) | (754,963) |
| Effect of foreign exchange differences | | 13,217 | _ | 472 | 13,689 |
| Balance as at September 30, 2019 | 13,021,618 | 18,643,035 | 29,557 | 628,550 | 32,322,760 |
| As at June 30, 2019 | | | | | |
| Cost | 13,282,660 | 19,138,601 | 81,069 | 947,175 | 33,449,505 |
| Accumulated depreciation | (230,868) | (2,247,236) | (56,916) | (339,153) | (2,874,173) |
| Net book value | 13,051,792 | 16,891,365 | 24,153 | 608,022 | 30,575,332 |
| As at September 30, 2019 | | | | | |
| Cost | 13,282,660 | 21,573,008 | 88,919 | 1,001,135 | 35,945,722 |
| Accumulated depreciation | (261,042) | (2,929,973) | (59,362) | (372,585) | (3,622,962) |
| Net book value | 13,021,618 | 18,643,035 | 29,557 | 628,550 | 32,322,760 |

Laboratory

The majority of property, plant and equipment is pledged as security for the credit facilities (Note 5).

As at September 30, 2019, there are \$2,476,948, \$2,148,497 and \$140,775 of building, production equipment and computers, respectively, that are not yet available for use and for which depreciation has not started [June 30, 2019 - \$2,476,948, \$3,362,135 and \$105,362].

The amount of borrowing costs capitalised in production equipment during the three-month period ended September 30, 2019 was \$201,643 [June 30, 2019 – nil]. The rate used to determine the amount of borrowing costs eligible for capitalisation was 6.76% which is the weighted average of the borrowing costs applicable to all borrowings of the entity that are outstanding during the period.

5. CREDIT FACILITIES

| | Maturity | Effective interest rate % | 2019 \$ | 2018 \$ |
|--|---------------|---------------------------|------------|------------|
| Operating loans, fixed and variable rate - Authorized amount of \$9,839,480 | 2019 and 2020 | 3.75% to 4.50% | 2,535,180 | 1,339,480 |
| Convertible debentures | December 2023 | 8% | 7,831,755 | 7,703,414 |
| Long-term debt | | | | |
| Term loan, fixed and variables rates | 2020 to 2028 | 4% to 10% | 15,490,490 | 16,080,096 |
| Lease liability | 2020 to 2028 | 0.79% to 5.5% | 8,615,551 | 8,782,901 |
| | | | 34,472,976 | 33,905,891 |
| Less: current portion of operating loans | | | 2,535,180 | 1,339,480 |
| Less: current portion of long-term debt | | | 5,661,290 | 4,170,072 |
| - | | _ | 26,276,506 | 28,396,339 |



[EXPRESSED IN CANADIAN DOLLARS]

Under these agreements, the Company has agreed to respect certain conditions and financial ratios. As at September 30, 2019, all conditions and financial ratios were met. Several movable hypothecs on specific assets of the Company and its subsidiaries and on the universality of the Company's present and future, tangible and intangible assets have been given as security for these loans and credit facilities.

6. EQUITY

Warrants and Broker Warrants

The following table summarizes the changes in the number of warrants outstanding for the three-month period ended September 30, 2019:

| | Number of warrants | Weighted average exercise price (\$) | |
|----------------------------------|--------------------|---|--|
| Balance as at June 30, 2019 | 12,684,935 | 1.10 | |
| Warrants exercised | (9,365,651) | 0.69 | |
| Warrants expired | (46,506) | 0.70 | |
| Balance as at September 30, 2019 | 3,272,778 | 2.25 | |

For the three-month period ended September 30, 2019, 8,909,994 First Warrants were exercised resulting in cash proceeds of \$6,236,996 and a transfer from reserve to share capital of \$590,635. The weighted average share price on the date of exercise of the warrants was \$1.42.

For the three-month period ended September 30, 2019, 455,657 Broker Warrants were exercised resulting in cash proceeds of \$205,045 and a transfer from reserve to share capital of \$59,051. The weighted average share price on the date of exercise of the warrants was \$1.39.

As at September 30, 2019, the following warrants were outstanding:

| | Number | Expiry Date | Exercise price (\$) |
|--|-----------|-------------|---------------------|
| Second Warrants issued as part of private placement | 3,030,350 | March 2020 | 2.30 |
| Broker Warrants issued as part of March 2018 private placement | 242,428 | March 2020 | 1.65 |

7. RELATED PARTY TRANSACTIONS

During the three-month period ended September 30, 2019, the following related party transactions have occurred with Martinrea International Inc., a shareholder of the Company with significant influence:

Exercise of 2,750,000 warrants for an amount of \$1,925,000.

During the three-month period ended September 30, 2019, the following related party transactions have occurred with Mason Graphite Inc., a shareholder of the Company with significant influence up to September 9, 2019:

- Exercise of 1,111,111 warrants for an amount of \$777,778.



[EXPRESSED IN CANADIAN DOLLARS]

8. SEGMENTED DISCLOSURE

Our Chief Operating Decision Maker analyzes the information for the Company as a whole on a consolidated basis only and, as such, the Company determined it has only one operating segment. Revenues are generated from our activities in Canada, in the United States and in Switzerland and all sales of products come from enhanced plastics and composite products.

| | Three-month periods ended September 30 | | |
|---|--|----------------|--|
| | 2019 | 2018 | |
| | \$ | \$ | |
| Revenues * | | | |
| Canada | 8,256,064 | 1,418,554 | |
| United States | 9,589,365 | 800,144 | |
| France | 1,300,560 | 893,413 | |
| Switzerland | 461,175 | 550,138 | |
| Other | 375,925 | 245,477 | |
| Total | 19,983,089 | 3,907,726 | |
| * Revenues are attributed to countries based on the location of customers | | | |
| | As at September | As at June 30, | |
| | 30, 2019 | 2019 | |
| | \$ | \$ | |
| Long-lived assets | | | |
| Canada | 38,886,406 | 35,417,980 | |
| Switzerland | 3,595,197 | 3,566,074 | |
| United States | 2,476,947 | 2,476,947 | |

9. COMMITMENTS

Total

The Company has committed to purchase raw materials to certain suppliers within two years and to purchase equipment for a total amount of \$10,077,286 for the construction of the graphene plant, on which \$2,919,270 were paid and included in the Consolidated Statement of Financial Position as Equipment deposits as at September 30, 2019.

44,958,550

41,461,001

As at September 30, 2019, the Company held options for a minimum of US\$5.0 million and a maximum of US\$10.8 million depending of the exchange rate of such derivatives contracts. Minimum rates vary from 1.2690 up to 1.3755. The contracts are valid until February 2021. The carrying value of the derivative foreign currency forward exchange contracts amounted to \$116,705 as at September 30, 2019 and was included in Accounts payable and accrued liabilities [June 30, 2019 – \$93,909].